Triantafyllos Tafas

QCDx LLC

Technologies

Medical Device

Indication

Autoimmune & Inflammation

Basic Research

Clinical Research

Clinical Trials

Disease surveillance

Drug Discovery

Genetics & Genomics

Molecular Diagnostic

Oncology

Personalized Medicine

Executive Summary

View/Download

Website

www.qcd-x.com

QCDx develops the RareScope™liquid biopsy for enrichment-free detection and isolation of intact and/or live Circulating Tumor Cells (CTC).
The RareScope can deliver early cancer diagnosis, monitoring of treatment efficacy and characterization of metastatic disease to aid in treatment optimization. Furthermore, it will be used for evaluating the effect of cancer drugs on CTCs before treatment is given to the patient.
A clinical study of the QCDx-br™ breast cancer diagnostic test with the University of Connecticut, Carol & Ray Neag Cancer Center, will begin enrolling patients on June 15, 2020.

2020 PITCH DAY VIDEO